Maria Shriver’s Women’s Alzheimer’s Research Challenge actively seeks to find out why women are disproportionately affected by Alzheimer’s and why women are at the epicenter of this disease. Answering that question requires a focus on what is particular to women’s biology, genetics, and lifestyle.
The Challenge has recruited five leading organizations and researchers in Alzheimer’s who have agreed to create “women’s Alzheimer’s research funds” to support high potential, gender-based research projects. 100% of the money raised through MOVE FOR MINDS will be distributed in grants from A Woman’s Nation to these exemplary organizations supporting researchers’ investigations will into sex-related, biological, genetic and lifestyle determinants. The money you sweat for will directly impact cutting-edge research on women’s brains at the following partner organizations.
The Alzheimer’s Association’s mission is to eliminate Alzheimer’s disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health.
The Alzheimer’s Association works on a global, national and local level to enhance care and support for all those affected by Alzheimer’s and other dementias. As the largest nonprofit funder of Alzheimer's research, the Association is committed to accelerating the global progress of new treatments, preventions and ultimately, a cure.
The Association reaches millions of people affected by Alzheimer’s across the globe through our national office and chapters in communities nationwide. They are the world’s leading voluntary health organization in Alzheimer’s care, support and research.
Cure Alzheimer's Fund is a non-profit organization dedicated to funding research with the highest probability of preventing, slowing or reversing Alzheimer's disease through venture-based philanthropy.
Since its founding, Cure Alzheimer’s Fund has contributed more than $36,000,000 to research, and its funded initiatives have been responsible for several key breakthroughs—including a potential treatment recently selected by the National Institutes of Health (NIH) for its elite “Blueprint” drug discovery program, and the ground-breaking “Alzheimer's in a Dish” study, which promises to greatly accelerate drug testing and was reported by the New York Times as a “giant step forward”.
Cure Alzheimer’s Fund supports some of the best scientific minds in the field of Alzheimer’s research, and it does so without any financial gain for its founders or donors. Fully 100 percent of funds raised by Cure Alzheimer’s Fund go directly to research—the Board of Directors covers all overhead expenses.
About Keep the Memory Alive: At Keep Memory Alive, we’re committed to improving the lives of patients and their families as they navigate the extraordinary challenges of brain disorders. Donations to Keep Memory Alive exclusively support Cleveland Clinic Lou Ruvo Center for Brain Health, which treats patients with Alzheimer's, Huntington's and Parkinson's disease, as well as frontotemporal dementia, multiple sclerosis and multiple system atrophy. The Lou Ruvo Center for Brain Health offers a unique model of integrated care, social services and research. Having conducted more than 40 clinical trials, the center is among the largest Alzheimer’s clinical research programs in the country.
The Ann Romney Center for Neurologic Diseases is transforming the future of medicine through novel forms of collaboration and patient-centered research. This collaboration—within and outside our walls—is accelerating the search for treatments, prevention, and cures for five of the world’s most complex neurologic diseases.
By combining Brigham and Women’s Hospital’s unique assets with the world’s most advanced resources and minds, the center is pursuing life-giving breakthroughs that are providing enduring hope and empowerment to individuals confronting these devastating neurologic diseases and changing outcomes for future generations.
The Ann Romney Center for Neurologic Diseases is a catalyst that fuels collaboration among the global medical and scientific communities in pursuit of treatments and cures for neurologic diseases.
Dr. Roberta Diaz Brinton is bringing precision medicine to persons with Alzheimer’s, to treat the right person, with the right therapeutic at the right time. She is an innovative and creative neuroscientist whose early insights yielded major breakthroughs in understanding the etiology of Alzheimer’s and developing therapeutics to prevent, delay and treat this devastating disease.
Dr. Brinton's insights, which predated the advent of precision medicine, formed the basis for programs of research critical to personalized therapeutic care for Alzheimer’s disease. Her current efforts utilize a precision medicine approach to identify combination therapies. Outcomes of her precision medicine research program, provide an unprecedented opportunity to evaluate existing treatments, create combination therapies personalized to the right person at the right time to prevent and treat Alzheimer’s disease.
An innovative scientist pursuing answers to one of this century’s greatest health challenges, Brinton has been recognized both nationally and internationally as a leader in the field. She was awarded "Scientist of the Year" by Alzheimer’s Drug Discovery Foundation, "Woman of the Year” by the California State Senate, Remarkable Woman by USC, "Science Educator of the Year” by the Society for Neuroscience, Los Angeles Magazine "Woman of the Year", and U.S. News & World Report's "Ten Best Minds". For her outstanding work in promoting STEM careers among students of color, President Barak Obama presented her with one of the nation's highest civilian honors, the Presidential Citizens Medal.
As a testament to both the rigor and importance of Dr. Brinton's science, her breakthrough research has been continuously funded by rigorously peer-reviewed grants from the National Institutes of Health (NIH) and private foundations including the Eileen and Kenneth Norris Foundation, which named her laboratory, the Alzheimer's Drug Discovery Foundation, the John D. French Foundation, the Whittier Foundation, the Paul Slavik Trust and the Alzheimer's Association.